Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
    Research/Science 1/27/2022

    At a glance
    In this general discussion post the tone is 😐 neutral.

    Other terms

    Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
    View this post in the Community →

    Similar Community Posts Join

    5 / 335 results

    Related Research

    6 / 138 results